Researchers from Clínic-IDIBAPS, as part of the Clínic Barcelona Comprehensive Cancer Centre — a centre driven by Clínic, IDIBAPS and the University1
The Home Care Unit (UAD) of the Clínic Barcelona Comprehensive Cancer Centre marked its 25th anniversary on 5 March 2026 with a commemorative event a1
A study led by the Clínic Barcelona Comprehensive Cancer Center —a center driven by Clínic-IDIBAPS and the University of Barcelona (UB)— demonstrates1
A study led by the Clínic-IDIBAPS reveals that the microbiota can predict and enhance patient response to one of the most innovative immunotherapies1
The Clínic Barcelona Comprehensive Cancer Center (4CB), driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona, has announced1
A team from Clínic-IDIBAPS has introduced a modification to a CAR-T immunotherapy for multiple myeloma that makes it more durable, according to resul1
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
